Scholars Central

Conference abstract

Development of a generic drug with different pharmaceutical features: A study of the therapeutic equivalence of mometasone nasal spray in patients with seasonal allergic rhinitis (Japanese cedar pollinosis)

Authors: Minoru Gotoh, Kumi Sugita, Akihiro Saito, Takayuki Honda, Koichiro Hoashi, Takashi Miyazaki

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

TAC-203 is under development as a generic drug for mometasone furoate, and it has pharmaceutical features different from those of original mometasone (OM): As a gel with a different viscosity is used, dripping after spraying and/or pouring the drug solution into the throat is greatly reduced. After the upper exhaust pressure airless spray container is adopted, there is no longer a difference in spraying performance due to differences in the angle of the container. As it is a homogeneous suspension, shaking before use has become unnecessary. No clinical studies in humans have been conducted so far for the development of generic steroid nasal sprays in Japan. However, since this drug has different pharmaceutical features from those of OM, we evaluated the efficacy and safety of the drug by conducting a high-quality therapeutic equivalence study in patients with seasonal allergic rhinitis. We conducted a randomized, evaluator-blinded, active and placebo-controlled study. Patients were randomly (2:2:1) assigned to receive TAC-203 (mometasone 200 μg/day), OM 200 μg/day, or placebo once daily for 2 weeks. The primary efficacy endpoint was the change from baseline in total nasal symptom score (TNSS) at 2 weeks. In addition, blood sample was collected at 1 hour after first administration for evaluating plasma mometasone concentration. 180 patients enrolled (TAC-203: 72, OM: 72, placebo: 36 patients, respectively). 95% confidence interval (-0.427 to 1.112) for the difference between treatments TAC-203-OM in the change from baseline in TNSS at 2 weeks was within the preplanned range of equivalence (-1.13 to 1.13). The geometric mean of mometasone furoate concentration in plasma was 8.85 pg/mL in TAC-203 and 4.87 pg/mL in OM. The therapeutic equivalence of TAC-203 and OM was confirmed by this study. Furthermore, TAC-203 has similar tolerability and safety profiles as OM. PDF HTML

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Clinical Research & Bioethics
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Minoru Gotoh”
  • BylineArticles whose byline prints “Kumi Sugita”
  • BylineArticles whose byline prints “Akihiro Saito”
  • BylineArticles whose byline prints “Takayuki Honda”
  • BylineArticles whose byline prints “Koichiro Hoashi”
  • BylineArticles whose byline prints “Takashi Miyazaki”